Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Indications  



1.1  Sexual  





1.2  Fat loss  





1.3  Other uses  







2 Pharmacology  





3 Production  





4 Adverse effects  





5 See also  





6 References  





7 External links  














Yohimbine






العربية
تۆرکجه
Български
Català
Čeština
Cymraeg
Deutsch
Español
فارسی
Français
Italiano
Nederlands

Polski
Português
Română
Русский
Саха тыла
Slovenčina
Slovenščina
Српски / srpski
Srpskohrvatski / српскохрватски
Suomi
Svenska

 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 




Print/export  







In other projects  



Wikimedia Commons
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


This is an old revision of this page, as edited by Space Cadet (talk | contribs)at06:14, 1 May 2011 (Other uses). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
(diff)  Previous revision | Latest revision (diff) | Newer revision  (diff)

Yohimbine
Clinical data
Routes of
administration
Oral
ATC code
Legal status
Legal status
Identifiers
  • 17α-hydroxy-yohimban-16α-
    carboxylic acid methyl ester

CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.005.157 Edit this at Wikidata
Chemical and physical data
FormulaC21H26N2O3
Molar mass354.44 g/mol (base)
390.90 g/mol (hydrochloride) g·mol−1
3D model (JSmol)
  • O=C(OC)[C@@H]5[C@H]4C[C@H]3c2nc1ccccc1c2CCN3C[C@@H]4CC[C@@H]5O

  • InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1 checkY

  • Key:BLGXFZZNTVWLAY-SCYLSFHTSA-N checkY

 ☒NcheckY (what is this?)  (verify)

Yohimbine is an alkaloid with stimulant and aphrodisiac effects found naturallyinPausinystalia yohimbe (Yohimbe). It is also found naturally in Rauwolfia serpentina (Indian Snakeroot), along with several other active alkaloids. Yohimbine has been used as both an over-the-counter dietary supplementinherbal extract form and prescription medicine in pure form for the treatmentofsexual dysfunction. Yohimbine was explored as a remedy for type 2 diabetes in animal and human models carrying polymorphisms of the α2A-adrenergic receptor gene.[1]

Indications

Sexual

The NIH states that yohimbine hydrochloride is the standardized form of yohimbine that is available as a prescription medicine in the United States, and has been shown in human studies to be effective in the treatment of male impotence.[2]

Yohimbine Hydrochloride, USP—a standardized form of yohimbine—is a prescription medicine that has been used to treat erectile dysfunction.[3] Controlled studies suggest that it is not always an effective treatment for impotence, and evidence of increased sex drive (libido) is anecdotal only.[4]


It cannot be excluded that orally administered yohimbine can have a beneficial effect in some patients with ED. The conflicting results available may be attributed to differences in drug design, patient selection, and definitions of positive response. However, generally, available results of treatment are not impressive.[5]

Yohimbine has been shown to be effective in the reversal of sexual satiety and exhaustion in male rats.[6] Yohimbine has also been shown to increase the volume of ejaculated semen in dogs, with the effect lasting at least five hours after administration.[7] Yohimbine has been shown to be effective in the treatment of orgasmic dysfunction in men.[8]

Fat loss

According to one study, oral yohimbine supplementation may actuate significant fat loss in athletes.[9] Numerous bodybuilding supplement companies sell formulations of yohimbine for transdermal delivery to effect a local reduction of adipose tissue, although there the experimental evidence for its efficacy is limited.[10][11]

Other uses

Yohimbine has also been used for the treatment of sexual side effects caused by some antidepressants (SSRIs), female hyposexual disorder, as a blood pressure boosting agent in autonomic failure, xerostomia, and as a probe for noradrenergic activity.

The addition of yohimbine to fluoxetineorvenlafaxine has also been found to potentiate the antidepressant action of both of these agents.[12]

Yohimbine has been used to facilitate recall of traumatic memories in the treatment of post traumatic stress disorder (PTSD).[13] Use of yohimbine outside therapeutic settings may not be appropriate for persons suffering from PTSD.[14] In pharmacology, yohimbine is used as a probe for α2-adrenoceptor. In veterinary medicine, yohimbine is used to reverse anesthesia from the drug xylazine in small and large animals.

Pharmacology

Yohimbine has high affinity for the α2-adrenergic receptor, moderate affinity for the α1-adrenergic, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1F, 5-HT2B, and D2 receptors, and weak affinity for the 5-HT1E, 5-HT2A, 5-HT5A, 5-HT7, and D3 receptors.[15][16] It behaves as an antagonist at α1-adrenergic, α2-adrenergic, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, and D2, and as a partial agonist at 5-HT1A.[15][17][18][19] Its intrinsic activities at the other sites listed are unclear/unknown but it is probably mostly antagonistic at them.

Production

Yohimbine is the principal alkaloid of the bark of the West African evergreen Pausinystalia yohimbe (formerly Corynanthe yohimbe), family Rubiaceae (Madder family). There are 31 other yohimbane alkaloids found in Yohimbe. In Africa, yohimbe has traditionally been used as an aphrodisiac.[3] However, it is very important to note that while the terms yohimbine, yohimbine hydrochloride, and yohimbe bark extract are related, they are not interchangeable.[2]

The main active chemical present in yohimbe bark is yohimbine HCl (indole alkaloid), found in the bark of the Pausinystalia yohimbe tree.

However, the levels of yohimbine that are present in yohimbe bark extract are variable and often very low.[2] Therefore, although yohimbe bark has been used traditionally to reduce male erectile dysfunction, there is not enough scientific evidence to form a definitive conclusion in this area.

Adverse effects

Yohimbine has significant side effects, such as anxiety reactions. According to the Mayo Clinic, yohimbine can be dangerous if used in excessive amounts.[20]

Higher doses of oral yohimbine may create numerous side effects, such as rapid heart rate, high blood pressure, overstimulation, insomnia and/or sleeplessness. Some effects in rare cases were panic attacks, hallucinations, headaches, dizziness, and skin flushing.[21]

More serious adverse effects may include seizures and renal failure. Yohimbine should not be consumed by anyone with liver, kidney, heart disease, or a psychological disorder.[21]

The therapeutic index of yohimbine is quite low; the range between an effective dose and a dangerous dose is very narrow.[21] This may also lead to precipitation of panic disorder type reactions.

Yohimbine in combination with modafinil causes dangerous acute rapid heart beat and acute increased blood pressure.

See also

References

  1. ^ Rosengren, A. H.; Jokubka, R.; Tojjar, D.; Granhall, C.; Hansson, O.; Li, D.-Q.; Nagaraj, V.; Reinbothe, T. M.; Tuncel, J. (2009). "Overexpression of Alpha2A-Adrenergic Receptors Contributes to Type 2 Diabetes". Science. 327 (5962): 217–20. doi:10.1126/science.1176827. PMID 19965390.
  • ^ a b c "Yohimbe: MedlinePlus Supplements". nlm.nih.gov. November 19, 2010. Retrieved December 13, 2010.
  • ^ a b Yohimbe. National Center for Complementary and Alternative Medicine.
  • ^ Andersson KE (2001). "Pharmacology of penile erection". Pharmacological Reviews. 53 (3): 417–50. PMID 11546836. {{cite journal}}: Unknown parameter |month= ignored (help)
  • ^ Andersson, Karl-Erik; Steers, William D. (1998). "The pharmacological basis of sexual therapeutics". In Morales, Alvaro (ed.). Erectile dysfunction: issues in current pharmacotherapy. London: Martin Dunitz. pp. 97–124 [114]. ISBN 978-1-85317-577-0. {{cite book}}: External link in |chapterurl= (help); Unknown parameter |chapterurl= ignored (|chapter-url= suggested) (help)
  • ^ Fernández-Guasti A, Rodríguez-Manzo G (2003). "Pharmacological and physiological aspects of sexual exhaustion in male rats". Scandinavian Journal of Psychology. 44 (3): 257–63. doi:10.1111/1467-9450.00343. PMID 12914589. {{cite journal}}: Unknown parameter |month= ignored (help)
  • ^ Yonezawa A, Yoshizumii M, Ebiko M, Amano T, Kimura Y, Sakurada S (2005). "Long-lasting effects of yohimbine on the ejaculatory function in male dogs". Biomedical Research. 26 (5): 201–6. doi:10.2220/biomedres.26.201. PMID 16295696. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  • ^ Adeniyi AA, Brindley GS, Pryor JP, Ralph DJ (2007). "Yohimbine in the treatment of orgasmic dysfunction". Asian Journal of Andrology. 9 (3): 403–7. doi:10.1111/J.1745-7262.2007.00276.x. PMID 17486282. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  • ^ Ostojic SM (2006). "Yohimbine: the effects on body composition and exercise performance in soccer players". Research in Sports Medicine. 14 (4): 289–99. doi:10.1080/15438620600987106. PMID 17214405.
  • ^ http://www.mesomorphosis.com/articles/volk/yohimbine-02.htm
  • ^ Yohimbe Info and ProductsatBodybuilding.com
  • ^ Dhir, A; Kulkarni, SK (2007). "Effect of addition of yohimbine (alpha-2-receptor antagonist) to the antidepressant activity of fluoxetine or venlafaxine in the mouse forced swim test". Pharmacology. 80 (4): 239–43. doi:10.1159/000104877. PMID 17622775.
  • ^ van der Kolk, Bessel A. (1995). "The Treatment of Post Traumatic Stress Disorder". In Hobfoll, Stevan E.; De Vries, Marten W. (eds.). Extreme stress and communities: impact and intervention. Boston: Kluwer Academic Publishers. pp. 421–44. ISBN 978-0-7923-3468-2. {{cite book}}: External link in |chapterurl= (help); Unknown parameter |chapterurl= ignored (|chapter-url= suggested) (help)
  • ^ Morgan CA, Grillon C, Southwick SM; et al. (1995). "Yohimbine facilitated acoustic startle in combat veterans with post-traumatic stress disorder". Psychopharmacology. 117 (4): 466–71. doi:10.1007/BF02246220. PMID 7604149. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  • ^ a b Millan MJ, Newman-Tancredi A, Audinot V; et al. (2000). "Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states". Synapse. 35 (2): 79–95. doi:10.1002/(SICI)1098-2396(200002)35:2<79::AID-SYN1>3.0.CO;2-X. PMID 10611634. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  • ^ "PDSP Ki Database".
  • ^ Arthur JM, Casañas SJ, Raymond JR (1993). "Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors". Biochemical Pharmacology. 45 (11): 2337–41. doi:10.1016/0006-2952(93)90208-E. PMID 8517875. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  • ^ Kaumann AJ (1983). "Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors". Naunyn-Schmiedeberg's Archives of Pharmacology. 323 (2): 149–54. doi:10.1007/BF00634263. PMID 6136920. {{cite journal}}: Unknown parameter |month= ignored (help)
  • ^ Baxter GS, Murphy OE, Blackburn TP (1994). "Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle". British Journal of Pharmacology. 112 (1): 323–31. PMC 1910288. PMID 8032658. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  • ^ Nippoldt, Todd B. Herbal viagra': Is it safe? Mayo Clinic
  • ^ a b c Prescription for Nutritional Healing, fourth edition Phyllis A. Balch, CNC
  • External links


    Retrieved from "https://en.wikipedia.org/w/index.php?title=Yohimbine&oldid=426847844"

    Categories: 
    Alpha blockers
    Monoamine oxidase inhibitors
    Anxiogenics
    Indole alkaloids
    Hidden categories: 
    CS1 errors: unsupported parameter
    CS1 errors: external links
    CS1 maint: multiple names: authors list
    CS1 errors: explicit use of et al.
    Drugs with non-standard legal status
    Articles with changed EBI identifier
    ECHA InfoCard ID from Wikidata
    Chem-molar-mass both hardcoded and calculated
    Infobox-drug molecular-weight unexpected-character
    Pages using infobox drug with unknown parameters
    Chemical pages without DrugBank identifier
    Articles without KEGG source
    Drugboxes which contain changes to verified fields
    Drugboxes which contain changes to watched fields
     



    This page was last edited on 1 May 2011, at 06:14 (UTC).

    This version of the page has been revised. Besides normal editing, the reason for revision may have been that this version contains factual inaccuracies, vandalism, or material not compatible with the Creative Commons Attribution-ShareAlike License.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki